



SENSIMED and NIDEK to cooperate in Japan



Lausanne, July 6th, 2011. Swiss-based company SENSIMED AG has developed the SENSIMED Triggerfish[®], a revolutionary contact lens for the continuous monitoring of fluctuations in intraocular pressure to facilitate the management of glaucoma. SENSIMED announced today the company has agreed a cooperation agreement with NIDEK CO., LTD. to support the clinical research phase and to develop the registration path for the SENSIMED Triggerfish[®] in Japan. Founded in Gamagori, Japan in 1971, NIDEK continues to be a global leader in the design, manufacture and distribution of ophthalmic equipment.

"Japan is one of the countries with the highest incidence of glaucoma, an increasing public health issue compounded with an ageing population. Furthermore, the prevalence of normal tension glaucoma makes it difficult for doctors to manage their glaucoma patients without having access to information on fluctuation of intraocular pressure during the full 24-hour period and in particular during sleep. We believe that the SENSIMED Triggerfish[®] can provide doctors with valuable information to stabilize their patients. We are very pleased to team up with a strong partner such as NIDEK to support the development of our technology in Japan. NIDEK has a strong organization to support our research clinical trials, and a very complementary product offering", says Jean-Marc Wismer, CEO of Sensimed.

Motoki Ozawa, President and CEO of NIDEK says, "NIDEK's mission is to provide fine products in many areas of the ophthalmology industry. Early detection and adequate treatment is one of the most important issues in medical practice. We are confident that the SENSIMED Triggerfish[®] will provide a new approach to glaucoma treatment in Japan. The cooperation between SENSIMED and NIDEK has enormous significance for both a community of eye care professionals and patients."

Glaucoma is an initially asymptomatic, progressive and irreversible degenerative disease of the optic nerve, leading to blindness unless adequate treatment is provided. Glaucoma is the second most common cause of blindness worldwide and affects about 70 million people. Intraocular pressure (IOP) is a major risk factor for glaucoma and the only treatable one. Circadian changes of IOP are dynamic and individual, with transient peaks and troughs over a 24-hour period. By providing ophthalmologists with the 24-hour profile of IOP, the SENSIMED Triggerfish[®] helps the doctor to better understand the condition of the patient, to provide personalized treatment, and to monitor the efficacy of the treatment over time.

About SENSIMED:

Established in 2003, Sensimed AG is a Swiss company with its principal focus on design, development and commercialization of integrated micro-systems for medical devices. Sensimed was spun off from the well renowned Swiss Federal Institute of Technology (EPFL) and grows within a world-leading cluster for medical devices in the lake of Geneva area. Sensimed has developed a new, patented, non-invasive product that will significantly improve identification and treatment of glaucoma disease by monitoring intraocular pressure around the clock. www.sensimed.ch

About NIDEK:

Established in 1971, NIDEK is a worldwide leader in the medical, optical and coating fields based on leading-edge optoelectronic technology. It develops, manufactures and sells products in the above fields, provide service and export the products internationally. It will continue to support people all over the world for their healthy lives as a leading company in the ophthalmic and optical instrument industries.

<http://www.nidek.co.jp>

SENSIMED AG

Route de Chavannes 37 • 1007 Lausanne • Switzerland

Tel. +41 21 621 9191 • Fax. +41 21 621 9193

www.sensimed.ch • info@sensimed.ch